GELTTECH BIO VALIDATION PAGE
Palm - free fatty-acid excipients from molecular farming.
Gelttech Bio is testing whether regional plant-based production can create traceable, palm-free, animal-free fatty-acid excipient inputs - starting with palmitic acid or palmitic-rich fraction. ttestingeG
A 90-day proof package, a go/no-go initiative moving forward, only if technical performance, economics, and market pull.
We are not asking stakeholders what would make this specific excipient route worth testing.
$50K
proof capital
TRL 2-3
90 days
go/no-go package
1 wedge
one molecule, one buyer class
Built for customer discovery, partner routing, and investor diligence. Non-confidential concept.
CUSTOMER PAIN HYPOTESIS
The problem is not "we need more molecular farming"
The first buyer's problem is supply-chain risk in formulation inputs: origin, traceability, animal-source constraints, palm exposure, price volatility, and qualification burden.
Excipient buyers
Need reliable inputs with documentation, batch quality, and supplier qualification clarity.
Formulation teams
Need functionally familiar molecules, not new chemistry that creates regulatory friction.
Investors and funders
Need a small, measurable proof package before financing a plataform-scale build
Palm exposure
Animal-source risk
Origen traceability
Supplier Concentration
COA expectations
Domestic manufacturing
PROPOSED ARCHITECTURE
Same usueful chemistry. A different source route.
Gelttech Bio is validating a regional molecular farming route for purified palmitic acid or palmitic-rich fatty-acid fractions. The concept is to use existing agricultural and downstream infrastructure where possible, rather than building a dedicated fermentation plant first.
1
Host + trait design
Select the crop or contained plant platform; define the C16 lipid-pathway strategy; set containment and identity-preservation requirements.
$48.16/kg
modeled fully burdened COGS, not measured
2
Production
Controlled greenhouse, contained propagation, or contract field production depending on host, regulatory status, and economics.
$80.26/kg
target sale price for 40% gross margin
3
Downstream + QC
Oil extraction, hydrolysis or fractionation, purification, and COA-style testing against relevant excipient expectations.
Level 1/5
buyer evidence:proxy only
CUSTOMER DISCOVERY
What evidence would make you ask for a sample?
Use this form to tell us whether the pain is real, which specification gates matter, and who should be in the next conversation.
Who we want to hear from
Excipient suppliers, CDMOs, formulation labs, plan biotech partners, oilseed processors, investors, non-dilutive funders, and public-sector supply chain stakeholders.
FAQ FOR FIRST CONVESATIONS
Questions we expect serious stakeholders to ask
Is this validated?
No. Current status is TRL 2-3. This page is designed to accelerate validation, not disguise the lack of mesured data.
What is the first product?
The initial focus is purified palmitic acid or a palmitic-rich fatty-acid fraction for exipient feedstocks and formulation inputs
Why not start with APIs?
APIs create longer clinical and regulatory paths. The first wedge is establish excipients chemistry where the main question is cource route, quality ,cost , and supplier qualification
What would make this fail?
Low targeted fatty-acid enrichment, poor purification recovery, unacceptable impurity profile, non-competitive COGS, weak buyer pull, or containment/regulatory friction that distroys the economics.